CATUG’s Post

Can Mitoquinol mesylate help prevent myocardial infarction? New research from the Semnan University of Medical Sciences, Iran has shed light on potential combined treatments for aged rats with myocardial infarction. Rats were treated with a combination therapy of mitoquinol mesylate and alpha-lipoic acid (ALA) for two weeks before undergoing artery occlusion and reperfusion. Those treated with this therapy had significantly improved cardiac function, with a reduction in pro-inflammatory cytokines TNF-α, IL-6, and IL-1β as well as apoptotic markers and a decrease in the percentage of TUNEL-positive cells (which detects DNA fragmentation). This further builds on evidence that mitoquinol mesylate has protective benefits for reperfusion injury in animal studies, especially in cardiac tissues. #mitoquinolmesylate #mitochondrialhealth #mitochondrialresearch #MCRP #cardiovascularhealth https://bit.ly/4dh7cl4

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐢𝐧 𝐋𝐢𝐯𝐞𝐫 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡! We are thrilled to share groundbreaking findings on the role of  𝐒𝐞𝐦𝐚𝐩𝐡𝐨𝐫𝐢𝐧-𝟑𝐀 𝐢𝐧 𝐥𝐢𝐯𝐞𝐫 𝐝𝐢𝐬𝐞𝐚𝐬𝐞, recently published in *Nature Cardiovascular Research*. The study highlights how elevated Sema3a impacts liver sinusoidal endothelial cells, contributing to metabolic dysfunction-associated steatotic liver disease (MASLD). 𝐏𝐚𝐦𝐆𝐞𝐧𝐞'𝐬 𝐤𝐢𝐧𝐚𝐬𝐞 𝐚𝐜𝐭𝐢𝐯𝐢𝐭𝐲 𝐩𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠 played a crucial role in this research, identifying key signaling pathways. This innovative technology is paving the way for targeted therapies, offering hope for reversing or preventing MASLD progression. Congratulations to the dedicated researchers for this significant achievement! Daniel Eberhard Sydney Balkenhol Eckhard Lammert 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞: 𝐍𝐚𝐭𝐮𝐫𝐞 𝐀𝐫𝐭𝐢𝐜𝐥𝐞 (https://lnkd.in/exs_MEvz) #LiverResearch #KinaseActivityProfiling #KinomePro #PamGene #MASLD #Biotechnology #HealthInnovation University of Düsseldorf, Faculty of Mathematics and Natural Sciences

Using a Bruker Avance IVDr* spectrometer enabled cardiology clinical researchers to perform discriminant analysis based on specific ischemic heart disease (IHD) microbiome and metabolome features to better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features. Read the article: https://lnkd.in/dx2vXTp8 Learn more about Bruker Avance IVDr and NMR* clinical research solutions and applications: https://lnkd.in/dNbiXsX9 Springer Nature Group *Bruker NMR Instruments are for Research Use Only. Not for Use in Clinical Diagnostic Procedures. #Metabolomics #Cardiovascular #Cardiology #CardiovascularDisease #NMR

And to start the weekend... New breakthrough in portal hypertension research ❗ I am excited to share the publication of a study developed with colleagues from Changzheng Hospital, Naval Medical University, Shanghai, now available to read in Gastroenterology. Big congrats to co-first authors, a privilege to co-supervise it from the very beginning. 🔶 Title: Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension. We discovered that HTR1A receptors in the portal vein are significantly up-regulated in both portal hypertensive rats and cirrhotic patients and, using diverse pre-clinical models including knock-out and knock-in models and primary cells, we demonstrated that these receptors play a crucial role in portal vein contraction via the cAMP pathway. Interestingly, the antispasmodic drug Alverine, an HTR1A antagonist, successfully reduced portal hypertension in rats. Clinical trials will be the next step. For the full article, you can read it here: https://lnkd.in/dNxG5Had. 🌟 The link is open access for 50 days, so do not miss the opportunity to learn more about portal hypertension pathophysiology! #MedicalResearch #LiverDiseases #TeamScience #PortalHypertension

📰 Publication alert: https://lnkd.in/dvfafNGc One of our key focus in EXIMIOUS_H2020 project is to understand the role of silicates in systemic autoimmunity and systemic autoimmune diseases. The present study by Lisa Janssen and Frauke Lemaire, in rodents will allow us to better understand the mechanism and complement our study in the occupational cohort. Here are some of the key findings ▶Silica exposure elicited a well-established inflammatory response in the lungs of both C57BL/6J and NOD/ShilLtJ mice. ▶These strains exhibited divergent responses in terms of respiratory function and lung volumes. ▶Slica exposure induced airway hyperreactivity and elevated antinuclear antibody levels in bronchoalveolar lavage fluid. ▶Lung tissue analysis revealed DEP loaded macrophages and co-localization of silica and DEP particles. ▶There was no evidence of synergistic or additive interaction between these specific doses of silica and DEP in inducing lung damage or inflammation in either of the mouse strains. #Exposome #silica #EHEN #EXIMIOUS

https://lnkd.in/eu7jbEaf The scientists used kidney samples from patients with CKD and WWP2-null kidney disease mice models and leveraged single-cell RNA sequencing analysis to detail the cell-specific regulation of WWP2 in fibrotic kidneys. Tubulointerstitial expression of WWP2 was associated with fibrotic progression in patients with CKD and in murine kidney disease models. Deficiency of WWP2 promoted myofibroblast proliferation and halted profibrotic activation, reducing the severity of renal fibrosis in vivo. In renal myofibroblasts, WWP2 deficiency increased fatty acid oxidation and activated the pentose phosphate pathway, boosting mitochondrial respiration at the expense of glycolysis. WWP2 suppressed the transcription of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a metabolic mediator of fibrotic response, and pharmacologic inhibition of PGC-1α partially cancelled the protective effects of WWP2 deficiency on myofibroblasts. Would boosting of PGC-1α with exercise, cold, ketosis, calorie restriction or supplements help in renal fibrosis and eventual failure?

Exciting advancements in the understanding of genetic predisposition to kidney disease and the role of antibodies in immune-mediated kidney diseases are paving the way for tailored medical treatments and improved patient outcomes. Dr. Geyhad ElGhazali, MD, PhD, Professor, Consultant Physician at PureLab South, highlights the potential for defining subgroups of patients that will benefit from specific therapeutic strategies, a promising development in the field of nephrology. The push for biomarker development to aid in the diagnosis, detection, and prediction of kidney disease is of utmost importance, particularly in a region experiencing a surge in cases. Read more on precision medicine for kidney disease at Omnia Health. #PureLab #PureHealth #AlwaysDependable #Medlab2024 #precisionmedicine

📃Scientific paper: Renal protective effects of astragalus root in rat models of chronic kidney disease Abstract: Background Astragalus root is a commonly used herb in traditional Chinese medicine. Although renoprotective effects have been reported in some clinical and experimental studies, the details remain unknown. Methods We used 5/6 nephrectomized rats as chronic kidney disease (CKD) models. At 10 weeks, they were divided into four groups, namely, CKD, low-dose astragalus (AR400), high-dose astragalus (AR800), and sham groups. At 14 weeks, they were sacrificed for the evaluation of blood, urine, mRNA expression in the kidney, and renal histopathology. Results Kidney dysfunction was significantly improved following astragalus administration (creatinine clearance: sham group; 3.8 ± 0.3 mL/min, CKD group; 1.5 ± 0.1 mL/min, AR400 group; 2.5 ± 0.3 mL/min, AR800 group; 2.7 ± 0.1 mL/min). Blood pressure, urinary albumin, and urinary NGAL levels were significantly lower in the astragalus-treated groups than those in the CKD group. Excretion of urinary 8-OHdG, an oxidative stress marker, and intrarenal oxidative stress were lower in the astragalus-treated groups than those in the CKD group. Furthermore, the mRNA expression of NADPH p22 phox, NADPH p47 phox, Nox4, renin, angiotensin II type 1 receptor, and angiotensinogen in the kidney was lower in the astragalus-treated groups compared with the CKD group. Conclusion This study suggests that astragalus root slowed CKD progression, possibly through the suppression of oxidative stress and the renin–angiotensin system. Continued on ES/IODE ➡️ https://etcse.fr/9RU ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Using a Bruker Avance IVDr* spectrometer enabled cardiology clinical researchers to perform discriminant analysis based on specific ischemic heart disease (IHD) microbiome and metabolome features to better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features. Read the article: https://lnkd.in/et3AAbxX Learn more about Bruker Avance IVDr and NMR* clinical research solutions and applications: https://lnkd.in/eKN_rcMV Springer Nature Group *Bruker NMR Instruments are for Research Use Only. Not for Use in Clinical Diagnostic Procedures. #Metabolomics #Cardiovascular #Cardiology #CardiovascularDisease #NMR

Researchers at Indiana University School of Medicine have identified a crucial protein marker that helps pinpoint cells capable of repairing damaged blood vessels. This breakthrough, published in the prestigious journal Circulation, opens the door to developing innovative therapies for endothelial dysfunction, a major contributor to coronary artery disease and related cardiovascular conditions. #medicalresearch #researchanddevelopment #research #innovation #cardivascular #heartdisease #lifesciences #indiana